Eiger Biopharmaceuticals, Inc. (EIGR) Stockholder News: Lead Plaintiff Deadline is Fast Approaching; Contact Robbins LLP for More Information SAN DIEGO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise...

Eiger Biopharmaceuticals, Inc. (EIGR) Equity Notice: Contact Robbins LLP if You Incurred Significant Damages From Your Investment in Eiger Biopharmaceuticals, Inc. SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise...

Eiger Biopharmaceutials, Inc. (EIGR) Class Action Notice: Contact Robbins LLP For Information if Eiger Biopharmaceutials, Inc. Harmed Your Financial Interests SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise...

Eiger Biopharmaceutials, Inc. (EIGR) Shareholder Update: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Eiger Biopharmaceutials, Inc. SAN DIEGO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise...

Eiger Biopharmaceuticals, Inc. (EIGR) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Eiger Biopharmaceuticals, Inc. SAN DIEGO, Nov. 11, 2022 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise...